Company News
CereMark Pharma is a West Virginia Limited Liability Company headquartered in Wheeling, WV, with an office in Lexington, KY. As a clinical-stage radiopharmaceutical company, we are focused on developing new and superior imaging tools that enable precision in predicting the development of Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE) in those individuals presenting with the uncertainty of mild cognitive impairment.
CereMark Pharma is privately held with 100% ownership by company founders and officers.
CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril
CereMark Prepares for Pivotal Phase 3 Clinical Trial for Prediction of Cognitive Decline in Alzheimer’s Disease, CTE and Other Neurodegenerative Diseases New York, New York - June 28, 2023 CereMark Pharma LLC (“CereMark”) today announced that it has entered into...
CereMark Pharma Announces F-18 Flornaptitril Supply Agreement with SpectronRx for Continued Development and Clinical Trials
CereMark Pharma Prepares for Phase 3 Clinical Study Initiation New York, New York – May 3, 2023 CereMark Pharma LLC (“CereMark”) today announced that it has entered into a supply agreement with SpectronRx for the production of [F-18]Flornaptitril (formerly...
CereMark Pharma Announces New Patents on Selective Imaging Agent of Alzheimer’s Disease, Chronic Traumatic Encephalopathy and Other Neurodegenerative Diseases
Los Angeles, California – August 2, 2022: CereMark Pharma LLC (“CereMark”) today announced that additional patents have been awarded to the University of California at Los Angeles (‘UCLA”) associated with a unique, selective imaging biomarker,...
Patent Awarded for PET Radiopharmaceutical for Neurodegeneration Imaging
CereMark clinical research studies show that Flornaptitril binds with both tau aggregates and beta amyloid plaque in the brain to enhance PET scan imaging. The distribution patterns of these pathological proteins are significant in both Chronic Traumatic...